ClinicalTrials.gg
CompletedNCT03262610Updated Jan 4, 2022

Setmelanotide in a Single Patient With Partial Lipodystrophy

A Phase 2 interventional study of Setmelanotide in Hypertriglyceridemia and Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 15 Years to 15 Years. Per ClinicalTrials.gov, last updated 2022-01-04.

Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
15 Years to 15 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 150 studies in Hypertriglyceridemia with a site in United States — 10 open to participants now, 16 under way, 4 of them phase 3. Hypertriglyceridemia · United States.

Enrollment
142nd of 145
1 · median 52
Started
2017
with 3 others
Phase 2
45 of 150
4 open now
Registered
102nd of 150
by date

Among the 150 studies in Hypertriglyceridemia with a site in United States, this one is the 142nd largest by enrollment of the 145 interventional ones that give a count, is one of 4 that started in 2017, is one of 45 in phase 2, and was the 102nd registered.

Hypertriglyceridemia

324 studies on the registry are indexed under Hypertriglyceridemia; 38 are open to participants now.

Browse Hypertriglyceridemia studies →

Open to participants now

10 of the 150 studies in Hypertriglyceridemia with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Hypertriglyceridemia studies recruiting now, 9 (41%) set no upper age limit and 12 (55%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 15 Years to 15 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Hypertriglyceridemia with a site in United States, or all of them as a file.
02

Study summary

The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.

Read the detailed description

This is a single-patient study to assess the safety and efficacy of setmelanotide in a unique patient with partial LD and severe metabolic abnormalities, most notably refractory hypertriglyceridemia leading to recurrent pancreatitis despite ongoing plasmapheresis treatment.

03

Conditions studied

  • Hypertriglyceridemia
  • Obesity
04

Who can participate

Ages eligible
15 Years to 15 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written
  2. Ability to comply with visits and procedures required by program.
  3. Has physician-confirmed partial lipodystrophy and the following characteristics:

    • Has atypical lipodystrophy.
    • Has presence of neutralizing antibody to metreleptin
    • Patient has life threatening hypertriglyceridemia and has had >8 episodes of pancreatitis, requiring weekly plasmapheresis
    • Has Type 1 diabetes mellitus with > 10%.
  4. Female, under the age of 18 years

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other (DSM-III) disorders that the investigator believes will interfere significantly with study compliance. Neurocognitive disorders affecting ability to consent will not be disqualifying as long as an appropriate guardian able to give consent has been appointed.
  2. History or close family history (parents or siblings) of skin cancer or melanoma, or patient history of ocular-cutaneous albinism.
  3. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions, determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist.
  4. Significant to study drug.
  5. Inability to comply with QD injection regimen.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Setmelanotide daily subcutaneous injection

    Up to 18 weeks setmelanotide treatment.

    Drug: Setmelanotide

Interventions

  • daily subcutaneous injection

    Also known as: RM-493

06

What researchers measure

Primary outcomes

  1. Fasting Triglycerides (TG) levels

    The mean change from baseline in fasting triglycerides after setmelanotide treatment.

    Time frame: 12 to 20 weeks

07

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Jan 2018, 5 months.

Of 23 phase 2 interventional studies under Hypertriglyceridemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2017
First posted
Aug 25, 2017
StartActual
Aug 15, 2017
Primary completionActual
Jan 31, 2018
CompletionActual
Jan 31, 2018
Last update
Jan 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03262610
Responsible party
Sponsor
First posted
Aug 25, 2017
Start date
Aug 15, 2017
Primary completion
Jan 31, 2018
Completion
Jan 31, 2018
Last update
Jan 4, 2022

Study contacts

Linda Shapiro, M.D., Ph.D.
study chair · Chief Medical Officer, Rhythm Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Setmelanotide

Start the discussion